(KNSA) |
|
0 (0%)
|
09-28 20:57 |
|
Open: |
|
Pre. Close: |
|
|
High:
|
|
Low:
|
|
|
Volume:
|
0 |
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2023-09-28 4:51:40 PM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 21.04 One year: 24.58 |
| Support: |
Support1: 16.89 Support2: 16.2 |
| Resistance: |
Resistance1: 18.02 Resistance2: 21.04 |
| Pivot: |
17.12 |
| Moving Average: |
MA(5): 16.93 MA(20): 17.15
MA(100): 15.97 MA(250): 14.48 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 57.5 %D(3): 36.4 |
| RSI: |
RSI(14): 53 |
| 52-week: |
High: 20.64 Low: 10.28 |
| Average Vol(K): |
3-Month: 488 (K) 10-Days: 293 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KNSA ] has closed below upper band by 28.6%. Bollinger Bands are 56.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
17.96 - 18.07 |
18.07 - 18.16 |
|
Low:
|
16.94 - 17.05 |
17.05 - 17.15 |
|
Close:
|
17.26 - 17.44 |
17.44 - 17.6 |
|
Company Description |
|
|
Headline News |
Thu, 28 Sep 2023
Amicus Therapeutics Upgrades RS Rating to 82, Becomes a Stock ... - Clayton County Register
Thu, 28 Sep 2023
Amicus Therapeutics Stock Reaches 80+ Relative Strength ... - Investor's Business Daily
Fri, 15 Sep 2023
Legato Capital Management LLC Buys New Position in Kiniksa ... - MarketBeat
Wed, 13 Sep 2023
Stocks With Rising Relative Strength: Ionis Pharmaceuticals - Investor's Business Daily
Fri, 08 Sep 2023
Ventyx Biosciences Gets Relative Strength Rating Upgrade - Investor's Business Daily
Fri, 08 Sep 2023
Intra-Cellular Therapies Shows Improved Relative Strength; Still Shy ... - Investor's Business Daily
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: |
| Sector: |
| Industry: |
| Shares Out. |
35 (M) |
| Shares Float |
30 (M) |
|
% Held by Insiders
|
4.6 (%) |
|
% Held by Institutions
|
96.3 (%) |
|
Shares Short
|
3,850 (K) |
|
Shares Short P.Month
|
3,440 (K) |
Stock Financials |
|
EPS
|
3.21 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
5.88 |
|
Profit Margin (%)
|
82.3 |
|
Operating Margin (%)
|
13.5 |
|
Return on Assets (ttm)
|
6.8 |
|
Return on Equity (ttm)
|
81.8 |
|
Qtrly Rev. Growth
|
165 |
|
Gross Profit (p.s.)
|
4.91 |
|
Sales Per Share
|
7.96 |
|
EBITDA (p.s.)
|
1.14 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
42 (M) |
|
Levered Free Cash Flow
|
37 (M) |
Stock Valuations |
|
PE Ratio
|
5.42 |
|
PEG Ratio
|
0.5 |
|
Price to Book value
|
2.96 |
|
Price to Sales
|
2.18 |
|
Price to Cash Flow
|
14.45 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
